Want to join the conversation?
$REGN and $SNY said SARIL-RA-MONARCH Phase 3 monotherapy study met its primary endpoint, showing that sarilumab was superior to adalimumab in improving symptoms in patients with active rheumatoid arthritis at week 24. Study also met secondary endpoints like other measures gauging improvements in signs and symptoms of RA and physical function.
$NFLX a monster move, going up. Expect making some money on Monday.
$AMD down more than 6% even after posting above consensus third quarter results.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.